Top Markets
#1 Black Phoenix Black Phoenix +324.80%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +57.52%
#4 Gold Park Gold Park +55.04%
#5 Acurast Acurast +30.18%
#6 BasedHype BasedHype +28.28%
#7 Cryptopia Cryptopia +22.67%
#8 Avantis Avantis +19.62%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.72%
#10 MYX Finance MYX Finance +16.77%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Affymax, Inc. Affymax, Inc.

Affymax, Inc.

AFFY
Rank in Stocks #41331
Affymax, Inc. presently lacks any substantial operational activities. In its... Affymax, Inc. presently lacks any substantial operational activities. In its earlier history, the firm concentrated on the creation of pharmaceutical agents designed to improve therapies for severe and frequently fatal health issues across the United States. Established in 2001, its corporate base is situated in New York, New York.
Share Price
$0.0007
Last synced: 2026-08-12
Market Cap
$26.24K
Change (1 day)
-56.25%
Change (1 year)
-12.50%
Country
US
Trade Affymax, Inc. (AFFY)

Category

Healthcare
Revenue for Affymax, Inc. (AFFY)
Revenue in Aug 2026 TTM: 0
According to Affymax, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Affymax, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE